Melanotan II vs Afamelanotide (Freckles)
Melanotan II and afamelanotide both activate melanocortin receptors to stimulate melanogenesis, yet they serve distinct clinical purposes. Melanotan II is a research peptide used for cosmetic tanning, while afamelanotide (Scenesse) is an FDA-approved implant for photoprotection in erythropoietic protoporphyria (EPP). Their receptor selectivity profiles produce fundamentally different pigmentation patterns and side effect profiles.
Molecular Identity
Section titled “Molecular Identity”Melanotan II
Section titled “Melanotan II”- Sequence: Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH₂
- Classification: Synthetic cyclic α-melanocyte-stimulating hormone (α-MSH) analog
- Molecular weight: ~1,023 Da
- Key feature: Cyclization via lactam bridge between Asp and Lys residues
Afamelanotide
Section titled “Afamelanotide”- Sequence: Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂
- Classification: Synthetic α-MSH analog (13-amino acid)
- Molecular weight: ~1,642 Da
- Key feature: Extended sequence with Nle4 substitution for metabolic stability
Receptor Selectivity
Section titled “Receptor Selectivity”| Receptor | Melanotan II | Afamelanotide |
|---|---|---|
| MC1R (skin pigmentation) | +++ | +++ |
| MC2R (cortisol) | + | ± |
| MC3R (energy homeostasis) | ++ | + |
| MC4R (appetite/satiation) | ++ | + |
| MC5R (exocrine function) | + | ± |
Melanotan II’s broader MC receptor profile accounts for its additional physiological effects (appetite suppression, sexual arousal, cardiovascular changes), while afamelanotide’s relative MC1R selectivity focuses its effects on pigmentation.
Pigmentation Characteristics
Section titled “Pigmentation Characteristics”Pattern of Tanning
Section titled “Pattern of Tanning”| Parameter | Melanotan II | Afamelanotide |
|---|---|---|
| Distribution | Uniform全身 | Sun-exposed areas |
| Color | Deep brown/bronze | Natural brown |
| Onset | 2–3 days (injectable) | 1–2 months (implant) |
| Duration | 1–3 months | ~2 months per implant |
| Response to UV | Enhanced | Enhanced |
| Freckling | Can produce | Does not produce |
Mechanism of Pigmentation
Section titled “Mechanism of Pigmentation”Melanotan II produces diffuse, uniform pigmentation through systemic MC1R activation. The broad receptor profile also produces melanogenesis in non-sun-exposed areas, creating an even tan that does not correspond to natural UV exposure patterns.
Afamelanotide produces pigmentation primarily in sun-exposed skin. The 13-amino acid sequence and sustained release from the subcutaneous implant produce gradual, natural-appearing tanning that follows UV exposure patterns. The pigmentation photoprotects by increasing eumelanin production, which absorbs UV radiation and scavenges free radicals.
Clinical Applications
Section titled “Clinical Applications”Melanotan II (Research/Cosmetic)
Section titled “Melanotan II (Research/Cosmetic)”| Application | Mechanism | Evidence |
|---|---|---|
| Cosmetic tanning | MC1R → melanogenesis | Anecdotal/preclinical |
| Sexual dysfunction | MC4R activation | Limited clinical data |
| Appetite suppression | MC3R/MC4R | Preclinical |
| Photoprotection | Increased melanin | Preclinical |
Melanotan II is not FDA-approved for any indication and is sold as a research chemical. Its use for cosmetic tanning is off-label and unregulated.
Afamelanotide (Therapeutic)
Section titled “Afamelanotide (Therapeutic)”| Application | Mechanism | Evidence |
|---|---|---|
| EPP photoprotection | Eumelanin ↑ → UV absorption | FDA-approved (Scenesse) |
| Solar urticaria | UV absorption | Phase III |
| Vitiligo repigmentation | Melanocyte stimulation | Phase II/III |
| Photoprotection in organ transplant | Melanin-mediated UV defense | Phase III |
Afamelanotide is FDA-approved (2019) for EPP and under investigation for other photoprotection indications.
Side Effect Profiles
Section titled “Side Effect Profiles”Melanotan II
Section titled “Melanotan II”| Side Effect | Incidence | Mechanism |
|---|---|---|
| Nausea | Common (30–50%) | MC3R/MC4R activation |
| Flushing | Common (40–60%) | MC1R → NO release |
| Appetite suppression | Common | MC4R activation |
| Sexual arousal | Common | MC4R → hypothalamic |
| Blood pressure changes | Occasional | MC receptor effects |
| Darkening of moles | Occasional | MC1R in melanocytes |
| Nausea/vomiting | Dose-limiting | Central MC4R |
Afamelanotide
Section titled “Afamelanotide”| Side Effect | Incidence | Mechanism |
|---|---|---|
| Headache | Common (15–25%) | Unknown |
| Nausea | Uncommon (<10%) | MC1R selective |
| Injection site reactions | Common | Implant-related |
| Cough | Uncommon | Unknown |
| Darkening of existing nevi | Expected | MC1R → melanogenesis |
| Influenza-like symptoms | Uncommon | Immune modulation |
Afamelanotide’s more favorable side effect profile reflects its MC1R selectivity and sustained, low-level receptor activation from the implant formulation.
Dosing and Administration
Section titled “Dosing and Administration”| Parameter | Melanotan II | Afamelanotide |
|---|---|---|
| Route | Subcutaneous injection | Subcutaneous implant |
| Dose | 0.5–1 mg SC daily (loading); 0.5–1 mg 2–3×/wk (maintenance) | 16 mg implant every 2 months |
| Loading period | 10–14 days | None (gradual onset) |
| Maintenance | 2–3× weekly injections | Every 2 months |
| Storage | Lyophilized, refrigerated | Room temperature |
| Self-administration | Yes (injection) | Physician-administered (implant) |
Freckle-Specific Considerations
Section titled “Freckle-Specific Considerations”For individuals specifically seeking freckle enhancement:
| Factor | Melanotan II | Afamelanotide |
|---|---|---|
| Freckle darkening | Yes (increases melanin in MC-rich areas) | Minimal (uniform pigmentation) |
| New freckle formation | Possible | Unlikely |
| Control over pattern | Low (systemic) | Low (sun-exposed areas) |
| Reversibility | Gradual fading (1–3 months) | Gradual fading (~2 months) |
Melanotan II may produce freckle darkening in individuals with pre-existing freckles, as MC1R activation in these melanocyte-rich areas enhances local melanogenesis. Afamelanotide’s more uniform pigmentation pattern is less likely to produce selective freckle enhancement.
Regulatory Status
Section titled “Regulatory Status”| Agent | FDA Status | EMA Status | Research Status |
|---|---|---|---|
| Melanotan II | Not approved; research chemical | Not approved | Phase I/II (limited) |
| Afamelanotide | Approved for EPP (Scenesse) | Approved for EPP | Phase III (solar urticaria, vitiligo) |
Key Takeaways
Section titled “Key Takeaways”Melanotan II and afamelanotide both stimulate melanogenesis through MC1R activation, but their receptor selectivity profiles, pigmentation patterns, and clinical applications differ substantially. Afamelanotide’s MC1R selectivity produces natural-appearing, sun-exposed pigmentation with a favorable side effect profile and FDA approval for EPP. Melanotan II’s broader receptor activation produces more intense but less natural pigmentation with more systemic side effects and no regulatory approval. For freckle-specific enhancement, neither agent provides precise control — both produce diffuse melanogenesis rather than selective freckle darkening.